Citi keeps a Neutral rating on Iqvia (IQV) with a $160 price target while adding a “downside 90-day short-term view” on the shares. The firm is cautious on Iqvia, citing delayed decision making by customers. The firm sees minimal upside to continued growth in the Technology and Analytics Solutions unit as comps get significantly harder in the second half of the year.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $190 from $210 at Mizuho
- Positive Outlook for IQVIA Holdings Driven by Resilient TAS, Strategic Capital Allocation, and R&D Strength
- Definitive Healthcare downgraded to Neutral from Buy at BTIG
- IQVIA Holdings: Strong Performance and Growth Potential Justify Buy Rating
- IQVIA Holdings: Strong Buy Rating Despite R&D Challenges and Valuation Opportunities